AN2 Therapeutics, Inc. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings
AN2 Therapeutics, Inc. (ANTX) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings · last filed 2023-03-29
- AN2 Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2022-12-31 was $0.00.
- AN2 Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2022-09-30 was $0.00.
- AN2 Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2022-06-30 was $0.00.
- AN2 Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2022-03-31 was $0.00.
- AN2 Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2022 was $0.00.
- AN2 Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2021 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $0.00 derived: sum of 2 quarters · filed 2023-03-29 | $0.00 derived: sum of 3 quarters · filed 2023-03-29 | $0.00 10-K · filed 2023-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-03-29 | $0.00 derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-29 | $0.00 derived: sum of 3 quarters · filed 2023-03-29 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $0.00 derived: sum of 2 quarters · filed 2023-03-29 | $0.00 10-K · filed 2023-03-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |